1. Akari Therapeutics Stock Plummets 21% Despite Major WuXi XDC Partnership Backing
Akari Therapeutics shares cratered by 21% in a single trading session, a sharp and significant decline that stands in stark contrast to the company's recent strategic announcement. The biotech firm had just secured a major partnership with WuXi XDC, a leading global biologics contract research, development, and manufac...